Company / Capital Expenditures
Entrada Therapeutics, Inc. Capital Expenditures History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$3.2M
FY2025
5-year range
$2.9M / $5.6M
FY2023-FY2025
Trend
-43.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $3M to $3M over the past 2 years.
Based on SEC 10-K filings.
$3M in FY2025.
Improved from $3M to $3M over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, capital expenditures decreased 43.7% year-over-year.
Company context
Key Data Points
- Altman Z-Score -2.03 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.2M | -43.7% |
| FY2024 | $5.6M | +94.5% |
| FY2023 | $2.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026